Answers are grounded in this paper and cite their sources.
Clinical study demonstrates circulating tumor DNA detection predicts survival in metastatic prostate cancer, highlighting its utility for early treatment adaptation.
In a recent study published in Nature Cancer , Jayaram and colleagues 1 demonstrated that persistent circulating tumor DNA detection during first-line intensified therapy independently predicts poor survival in patients with metastatic castration-sensitive prostate cancer, providing prognostic information earlier than prostate-specific antigen (PSA) kinetics. These findings support circulating tumor DNA as a promising dynamic biomarker for early treatment adaptation and highlight its potential to complement PSA in guiding precision therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Roviello et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: